Equities researchers at StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.
ProPhase Labs Price Performance
NASDAQ:PRPH opened at $0.44 on Tuesday. ProPhase Labs has a 52 week low of $0.22 and a 52 week high of $7.48. The stock’s fifty day moving average is $0.52 and its two-hundred day moving average is $1.42. The company has a market capitalization of $10.51 million, a P/E ratio of -0.35 and a beta of -0.37. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new position in ProPhase Labs in the 4th quarter valued at about $36,000. Squarepoint Ops LLC acquired a new stake in shares of ProPhase Labs during the fourth quarter worth $40,000. Warberg Asset Management LLC purchased a new position in ProPhase Labs in the 4th quarter valued at $77,000. Perritt Capital Management Inc increased its stake in ProPhase Labs by 129.1% in the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after buying an additional 107,068 shares during the period. Finally, Geode Capital Management LLC raised its position in ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after buying an additional 42,793 shares during the last quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Read More
- Five stocks we like better than ProPhase Labs
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Buffett’s on the Sidelines – Should You Follow?
- There Are Different Types of Stock To Invest In
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Energy and Oil Stocks Explained
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
